{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:17:34Z","timestamp":1784618254783,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001080","name":"Patrick and Catherine Weldon Donaghue Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG024824"],"award-info":[{"award-number":["P30AG024824"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jamda.2020.05.039","type":"journal-article","created":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T16:36:09Z","timestamp":1595090169000},"page":"1629-1635.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011\u20132014"],"prefix":"10.1016","volume":"21","author":[{"given":"Lauren B.","family":"Gerlach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen C.","family":"Kales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjin Myra","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie P.W.","family":"Bynum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Strominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan T.","family":"Maust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2020.05.039_bib1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1532-5415.1992.tb01996.x","article-title":"The impact of OBRA on medical practice within nursing facilities","volume":"40","author":"Elon","year":"1992","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jamda.2020.05.039_bib5","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2020.05.039_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamainternmed.2018.0379","article-title":"Association of the Centers for Medicare & Medicaid Services\u2019 national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014","volume":"178","author":"Maust","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2020.05.039_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.7.3.314","article-title":"Valproate in the treatment of behavioral agitation in elderly patients with dementia","volume":"7","author":"Lott","year":"1995","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.jamda.2020.05.039_bib8","first-page":"505","article-title":"Carbamazepine in senile dementia and overactivity - a placebo controlled double-blind trial","volume":"10","author":"Chambers","year":"1982","journal-title":"Ircs Medical Science-Biochemistry"},{"key":"10.1016\/j.jamda.2020.05.039_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00004714-200002000-00015","article-title":"Effectiveness of gabapentin for the treatment of behavioral disorders in dementia","volume":"20","author":"Herrmann","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jamda.2020.05.039_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/13607863.2016.1277974","article-title":"Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care","volume":"22","author":"Olivieri-Mui","year":"2018","journal-title":"Aging Ment Health"},{"key":"10.1016\/j.jamda.2020.05.039_bib11","first-page":"12","article-title":"The impact of OBRA '87 on psychiatric services in nursing homes - Joint testimony of the American Psychiatric Association and the American Association for Geriatric Psychiatry","volume":"7","author":"Colenda","year":"1999","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s10742-010-0060-4","article-title":"Identifying types of nursing facility stays using medicare claims data: an algorithm and validation","volume":"10","author":"Yun","year":"2010","journal-title":"Health Services & Outcomes Research Methodology"},{"key":"10.1016\/j.jamda.2020.05.039_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.jamda.2020.05.039_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/geront\/40.6.663","article-title":"The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Epidemiology of Dementia in Nursing Homes Research Group","volume":"40","author":"Magaziner","year":"2000","journal-title":"Gerontologist"},{"key":"10.1016\/j.jamda.2020.05.039_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/gps.589","article-title":"Incidence, prevalence, and outcomes of depression in residents of a long-term care facility with dementia","volume":"17","author":"Payne","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1377\/hlthaff.28.3.689","article-title":"Mental illness in nursing homes: variations across states","volume":"28","author":"Grabowski","year":"2009","journal-title":"Health Aff"},{"key":"10.1016\/j.jamda.2020.05.039_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2012.211266","article-title":"Antipsychotic use among nursing home residents","volume":"309","author":"Briesacher","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2020.05.039_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib19","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1136\/bmj.e977","article-title":"Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study","volume":"344","author":"Huybrechts","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2020.05.039_bib20","doi-asserted-by":"crossref","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jamda.2020.05.039_bib21","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2020.05.039_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","article-title":"Gabapentinoid use in the United States 2002 through 2015","volume":"178","author":"Johansen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2020.05.039_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u2014is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jamda.2020.05.039_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/089719000001300408","article-title":"Anticonvulsant use in treating dementia-related agitation","volume":"13","author":"Gardner","year":"2000","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.jamda.2020.05.039_bib25","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1177\/089198879500800105","article-title":"Anticonvulsant and other non-neuroleptic treatment of agitation in dementia","volume":"8","author":"Tariot","year":"1995","journal-title":"J\u00a0Geriatr Psychiatry Neurol"},{"key":"10.1016\/j.jamda.2020.05.039_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A\u00a0clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jamda.2020.05.039_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.genhosppsych.2009.02.006","article-title":"How reviews covered the unfolding scientific story of gabapentin for bipolar disorder","volume":"31","author":"Williams","year":"2009","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jagp.2015.07.001","article-title":"Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004\u20132013","volume":"23","author":"Vasudev","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/bmjqs-2018-007840","article-title":"Public reporting of antipsychotic prescribing in nursing homes: population-based interrupted time series analyses","volume":"28","author":"Ivers","year":"2019","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jamda.2020.05.039_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0004867418758919","article-title":"More action needed: Psychotropic prescribing in Australian residential aged care","volume":"53","author":"Westbury","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jamda.2020.05.039_bib31","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/13607863.2017.1348469","article-title":"Psychotropic drug prescription for nursing home residents with dementia: prevalence and associations with non-resident-related factors","volume":"22","author":"Smeets","year":"2018","journal-title":"Aging Ment Health"},{"key":"10.1016\/j.jamda.2020.05.039_bib32","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1017\/S1041610213000859","article-title":"Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings","volume":"25","author":"Gustafsson","year":"2013","journal-title":"Int Psychogeriatr"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861020304461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861020304461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:24:07Z","timestamp":1761506647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861020304461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1525861020304461"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2020.05.039","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011\u20132014","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2020.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AMDA - The Society for Post-Acute and Long-Term Care Medicine.","name":"copyright","label":"Copyright"}]}}